No clinically relevant drug–drug interactions when dalcetrapib is co-administered with atorvastatin

Bibliography

• Fruchart JC, Sacks F, Hermans MP, The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102(10 Suppl):1K-34K
   PubMed Web of Science ®Google Scholar
• Robins SJ, Collins D, Wittes JT, ; VA-HIT Study Group. Veterans affairs high-density lipoprotein intervention trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91
   PubMed Web of Science ®Google Scholar
• Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006;97:477-9
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Goldbourt U, Boyko V, ; BIP Study Group. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial). Am J Cardiol 2006;97:466-71
   PubMed Web of Science ®Google Scholar
• Inazu A, Brown ML, Hesler CB, Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323:1234-8
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Kuivenhoven JA, Wareham NJ, Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 2004;110:1418-23
   PubMed Web of Science ®Google Scholar
• Stein EA, Stroes ES, Steiner G, Safety and tolerability of dalcetrapib. Am J Cardiol 2009;104:82-91
   PubMed Web of Science ®Google Scholar
• Stein EA, Roth EM, Rhyne JM, Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010;31:480-8
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159-65
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81
   PubMed Web of Science ®Google Scholar
• Derks M, Abt M, Phelan M, Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug–drug interactions. J Clin Pharmacol In press, DOI: 10.1177/0091270009358709
   Google Scholar
• Derks M, Fowler S, Kuhlmann O. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin 2009;25:891-902
   PubMed Web of Science ®Google Scholar
• Derks M, Fowler S, Kuhlmann O. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clin Ther 2009;31:586-99
   PubMed Web of Science ®Google Scholar
• Lau YY, Okochi H, Huang Y, Benet LZ. Multiple transporters affect the disposition of atorvastatin ans its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 2006;316:762-71
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;122:71-105
   Web of Science ®Google Scholar
• Bogman K, Peyer AK, Torok M, HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001;132:1183-92
   PubMed Web of Science ®Google Scholar
• Chen C, Lin J, Smolarek T, Tremaine L. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug Metab Dispos 2007;35:1725-29
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, de Grooth GJ, Kawamura H, Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085-8
   PubMed Web of Science ®Google Scholar
• Moren X, Deakin S, Liu M-L, HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress. J Lipid Res 2008;49:1246-53
   PubMed Web of Science ®Google Scholar
• Mirdamadi HZ, Sztanek F, Derdak Z, The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol 2008;66:366-74
   PubMed Web of Science ®Google Scholar
• Nagila A, Permpongpaiboon T, Tantrarongroj S, Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep 2009;61:892-8
   PubMed Web of Science ®Google Scholar
• Guerin M, Lassel TS, Le Goff W, Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000;20:189-97
   PubMed Web of Science ®Google Scholar
• Kassai A, Illyes L, Mirdamadi HZ, The effect of atorvastatin therapy on lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem 2007;40:1-5
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ballantyne CM, Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009;158:896-901
   PubMed Web of Science ®Google Scholar